Arcutis Biotherapeutics (ARQT) Stock Price
$13.67 1.9%
to add to portfolio
AI Score
-
Alternative
4 -
Fundamental
7 -
Technical
7
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Arcutis Biotherapeutics, AI stock picks, stock alerts and much more.
ARQT AI Stock Analysis
Financial Performance
Arcutis Biotherapeutics has shown strong growth in its financial performance. The company's revenue of $44.8M, up by 45% from the previous quarter and 230.9% year over year, indicates a solid trend of increasing sales. Their gross profit at $39.3M is also on an upward trajectory, with a rise of 43.3% from the previous quarter and a significant increase of 254.2% YoY. However, their operating income is negative at -$39.1M but it improved by 22% QoQ and by 36.1% YoY which shows that they are effectively managing their expenses to improve profitability over time.
Stock Price
The stock price for Arcutis Biotherapeutics has been performing well with an increase of 27.8% in the last month, and an impressive jump of 420.1% YoY indicating strong investor confidence in the company's prospects despite its negative PE ratio (-7.60) and EPS (-1.67). The RSI value stands at around mid-range (66), suggesting that the stock is neither oversold nor overbought while the stock's price being above its 200-day moving average ($9.75) implies positive momentum.
Alternative Data Signals
The alternative data signals present mixed results for Arcutis Biotherapeutics' future prospects as web traffic numbers have increased MoM but decreased YoY indicating inconsistent interest online towards the company.The lack of job openings could suggest cost-cutting measures or simply no need for expansion currently.Employee sentiment regarding business outlook appears neutral which may not be enough to drive significant changes in stock performance.Finally,the social media followers count shows growth on Twitter but a slight decline on Facebook,indicating mixed sentiment among the company's social media audience.
Conclusion
In conclusion,the analysis of Arcutis Biotherapeutics' stock is neutral to slightly bullish.The company's strong revenue and gross profit growth,along with its improving operating income and positive stock price momentum are promising signs.However,the negative PE ratio,EPS and mixed alternative data signals suggest some caution is warranted.
Note: This AI Stock Analysis is based on data as of December 14. Our members can refresh and get access to an up-to-date AI stock analysis.
Sign up
Arcutis Biotherapeutics (ARQT) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Arcutis Biotherapeutics (ARQT), currently trading at $13.67, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About ARQT
-
Arcutis Biotherapeutics, Inc.
-
Symbol
ARQT
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
1.6B
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$23.91 4.7% |
6 |
 |
Inovio Pharmaceuticals INO |
$2.15 1.8% |
4 |
 |
Moderna MRNA |
$43.59 3% |
4 |
 |
Anavex Life Sciences AVXL |
$9.73 1.8% |
6 |
 |
BridgeBio Pharma BBIO |
$36.32 0% |
7 |
News
ARQT Alternative Data
Web Traffic
Arcutis Biotherapeutics receives an estimated 22551 monthly visitors to arcutis.com.
-
Web Traffic
22551
-
Change from Previous Month
10.2%
-
3 Month Change
13.9%
-
YoY Change
13.9%
News Mentions
Arcutis Biotherapeutics was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
100%
Twitter Followers
Arcutis Biotherapeutics has 561 Twitter Followers on its main Twitter (also known as X) account, which is up by 1.6% over the last month.
-
Twitter Followers
561
-
Daily Change
0%
-
1 Month Change
1.6%
-
3 Month Change
1.4%
-
YoY Change
1.4%
Facebook Engagement
Arcutis Biotherapeutics has engaged 2 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
2
-
Daily Change
71.4%
-
1 Month Change
75%
-
3 Month Change
50%
-
YoY Change
50%
LinkedIn Followers
23,306 are following Arcutis Biotherapeutics on LinkedIn, up by 1.8% over the last month.
-
LinkedIn Followers
23306
-
Daily Change
0.1%
-
1 Month Change
1.8%
-
3 Month Change
5.8%
Job Postings
Arcutis Biotherapeutics has an estimated 5 open job postings, which is down -37.5% over the last month.
-
Job Postings
5
-
Daily Change
0%
-
1 Month Change
37.5%
-
3 Month Change
58.3%
-
YoY Change
58.3%
LinkedIn Employees
According to LinkedIn, Arcutis Biotherapeutics has 360 employees, up by 1.1% over the last month.
-
LinkedIn Employees
360
-
Daily Change
0%
-
1 Month Change
1.1%
-
3 Month Change
3.2%
-
YoY Change
3.2%
Business Outlook
-
Business Outlook
49
-
Change from Previous Month
0%
-
3 Month Change
0%
-
YoY Change
0%
ARQT Financials
ARQT Key Metrics
-
Total Revenue
$44.8M
-
Net Income
-$41.5M
-
Earnings per Share
-$0.0003
-
Free cash flow
-$34.8M
-
EBITDA
-$39.1M
-
EBITDA Ratio
-0.872886
-
Total Assets
$437.4M
ARQT 2-year Revenue & Income
ARQT 2-year Free Cash Flow
ARQT Technicals
ARQT SMA
ARQT RSI
FAQ
What's the current price of Arcutis Biotherapeutics (ARQT) Stock?
The price of an Arcutis Biotherapeutics (ARQT) share is $13.67.
What's the market cap of Arcutis Biotherapeutics?
The current market cap of Arcutis Biotherapeutics is 1.6B.
Should I buy or sell ARQT?
Arcutis Biotherapeutics shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Arcutis Biotherapeutics is better viewed as a hold or accumulate position while waiting for further developments.
Is Arcutis Biotherapeutics a good investment?
The current analysis of Arcutis Biotherapeutics' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Arcutis Biotherapeutics' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Arcutis Biotherapeutics (ARQT) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Arcutis Biotherapeutics stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Arcutis Biotherapeutics (ARQT) that investors often compare it to?
Arcutis Biotherapeutics (ARQT) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Arcutis Biotherapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Arcutis Biotherapeutics' stock price to be around $14.02 in 2026. Starting from the current price of $13.67, this represents a 2.6% change in price, indicating a neutral outlook for the stock.
How to buy Arcutis Biotherapeutics (ARQT) Stock?
Arcutis Biotherapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Arcutis Biotherapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.